Australia’s Age Pension is very generous and offers a number of positives, including protection against inflation. If I were relying on income, I’d rather receive payments from Argo Investments Ltd (ASX: ARG) and other ASX dividend stocks.

Argo Investments is one of Australia’s oldest and largest listed investment companies (LICs). It was founded in 1946 and has clearly succeeded with its targets.

It speaks volumes that cricketing legend Don Bradman joined the board in 1954 and served until 1984. Argo’s strategy has been steady, long-term investing, resulting in solid performance of the portfolio.

Let’s run through why the business is so appealing today.

Diversification

The job of an LIC is to invest in other shares/assets to generate investment returns.

Argo’s portfolio is focused on large ASX shares that enable the LIC to provide reliable fully-franked dividend income and capital growth.

For pleasing diversification, Argo has invested across an array of ASX shares.

At the end of September 2026, the businesses that were a weighting of more than 3% in the Argo portfolio, included BHP Group Ltd (ASX: BHP), Macquarie Group Ltd (ASX: MQG), Rio Tinto Ltd (ASX: RIO), Commonwealth Bank of Australia (ASX: CBA), ANZ Group Holdings Ltd (ASX: ANZ), Wesfarmers Ltd (ASX: WES), Westpac Banking Corp (ASX: WBC), CSL Ltd (ASX: CSL), Santos Ltd (ASX: STO), Telstra Group Ltd (ASX: TLS), National Australia Bank Ltd (ASX: NAB), and Aristocrat Leisure Ltd (ASX: ALL).

As you can see, it’s many of the ASX’s leading blue chips.

Its performance has been solid – at 30 June 2026, its pre-tax net tangible assets (NTA) after costs was stronger than the S&P/ASX 200 Accumulation Index (ASX: XJOA) over the prior six months, 12 months, three years, and five years.

That solid performance has been good enough for the ASX dividend stock to pay good passive income over the last few years.  

Rising dividends

After a difficult start to the 2020s following COVID-19 impacts, the LIC increased its payout in FY22 and FY23, maintained the payout in FY24, grew it in FY25, and hiked again in FY26.

Pleasingly, the company has guided that it plans to hike the dividend again in FY27 to 40 cents per share with four quarterly dividends of 10 cents per share.

The FY27 payout would represent a year-over-year increase of 3.9%, so it essentially matches the current elevated rate of inflation.

Good dividend yield

Argo can provide investors with a solid dividend yield, which I think is appealing. I’d rather have a mixture of yield and long-term growth rather than a big yield and no growth (or declines).

At the time of writing, and based on the guided annual dividend of 40 cents per share, it translates into a forward dividend yield of 4.4% excluding franking credits and 6.3% including franking credits.

This is much more appealing passive income than what’s on offer from Vanguard Australian Shares Index ETF (ASX: VAS).

How much of the ASX dividend stock it would take to match the Australian Age Pension

Currently, the maximum annualised Age Pension that a single person can receive is approximately $32,180.

To receive that much from Argo in relation to its FY27 dividend, an investor would need to buy 80,450 shares. Considering (at the time of writing) it’s trading at a discount of 17% to its pre-tax net tangible assets (NTA) at 16 October 2026, I think it’s a good time to buy. But, I’d also want to invest in other ASX dividend stocks too for dividend diversification.

The post 80,450 shares of this ASX dividend stock pays an income equal to the Age Pension appeared first on The Motley Fool Australia.

More reading

• 2 ASX blue-chip shares offering big dividend yields
• How much do I need to retire on $110,000 a year at 65?
• How much is needed in superannuation to target a $95,000 annual passive income?
• 2 ASX blue-chip shares offering big dividend yields
• This outperforming ASX dividend stock will now pay out on a quarterly basis

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, and Wesfarmers. The Motley Fool Australia has positions in and has recommended Telstra Group. The Motley Fool Australia has recommended BHP Group, CSL, Macquarie Group, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Morgans has been busy running the rule over a number of ASX shares.

Three that have fared well and been given buy ratings are listed below. Here’s why the broker is bullish on them:

ARB Corporation Ltd (ASX: ARB)

Morgans was a touch disappointed with this 4×4 parts manufacturer’s performance during the first quarter.

However, it remains positive on the future and has retained its buy rating with a $25.90 price target. This implies potential upside of over 50% for investors.

Commenting on ARB, Morgans said:

ARB’s 1Q27 update was disappointing: sales -6.1% (1Q26 +3.8%) as Aftermarket and Export weakness (single-digit declines) outweighed strong OEM growth. Positively, PBT grew despite weaker sales amid steady gross margins (FX-driven). While a softer Aftermarket result was largely expected (ARB’s core vehicle volumes -16% in 1Q27), Export was a negative surprise, as slower US OEM sales, softer UK vehicle volumes and weak NZ demand offset growth in the US Aftermarket, Africa, Europe and SE Asia. 

Positively, new OEM contract wins and early indications of recovering OEM sales support the division’s outlook. Despite softer near-term sales, resilient margins should continue to underpin the earnings base, with improving vehicle supply and various network and growth initiatives driving the earnings recovery. BUY maintained, A$25.90ps target price.

Navigator Global Investments Ltd (ASX: NGI)

The broker highlights that this global investment company delivered a mixed quarter.

Nevertheless, it remains positive and has retained its buy rating and $3.04 price target. This suggests that the ASX share could rise around 46% from current levels.

The broker commented:

NGI has released its September 2026 (1Q27) AUM update. We saw this as a bit of a mixed quarter. Group ownership-adjusted AUM rose +9% (or a solid ~+3% excluding Stable Growth), led by the NGI Strategic Portfolio (+9%). 

However, Lighthouse was softer, with net flows slowing to +US$280m (4Q26: +US$690m), being mostly into lower-margin managed accounts, and largely offset by negative performance (-US$240m). We make no changes to our forecasts or our A$3.04 price target. With >20% upside remaining to our PT, we maintain our BUY recommendation.

Netwealth Group Ltd (ASX: NWL)

A third ASX share that has been given the thumbs up from Morgans is investment platform provider Netwealth.

Once again, although Netwealth’s quarterly performance fell short of expectations, Morgans still sees plenty of value in its shares. 

As a result, it has retained its buy rating with a $22.90 price target. It said:

NWL’s 1Q27 net flows of A$2.6bn were below VA consensus (A$3.5bn), with elevated gross outflows persisting (incl. two institutional client exits totalling A$0.6bn). Group FUA grew +2.5% QoQ to a record A$139.2bn, ~1.3% shy of VA consensus (A$141.0bn), with markets a slight +A$0.8bn tailwind. FY27 net flows guidance was lowered to A$17-19bn, with NWL flagging budget impacts & market volatility as current headwinds to adviser/investor behaviour. 

We trim our FY27-29F NPAT forecasts by -5-6% reflecting a modest miss vs MorgF, and the addition of Paradino into MorgansF. NWL is trading on a FY27 P/E of ~30x (a -35% discount to its 5yr avg). Our BUY rating is retained with a PT of A$22.90/sh.

The post Morgans names 3 ASX shares to buy now appeared first on The Motley Fool Australia.

More reading

• 2 ASX shares highly recommended to buy: Experts
• 3 ASX 200 shares to buy and why: Ord Minnett
• I looked at the bear case for these 3 ASX shares, and came to a different conclusion. Here’s why
• 3 ASX shares UBS has tipped to increase 44% to 76%
• WiseTech Global vs Netwealth: Which ASX tech stock could double from here?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ARB Corporation and Netwealth Group. The Motley Fool Australia has positions in and has recommended Netwealth Group. The Motley Fool Australia has recommended ARB Corporation. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today following the company’s Q3 2026 results, which saw group revenue grow 19% year on year to US$245 million, with Precision Medicine revenue jumping 30% to US$201 million.

What did Telix Pharmaceuticals report?

• Group revenue rose 19% versus Q3 2025 to US$245 million.
• Precision Medicine revenue increased 30% to US$201 million, driven by Illuccix and Gozellix.
• FDA approved Pixclara for glioma imaging; first U.S. commercial doses administered in September 2026.
• BiPASS Phase 3 prostate cancer study completed enrolment; FDA granted Fast Track Designation.
• Merger with Isotope Technologies Munich SE (ITM) announced, boosting therapeutics pipeline and isotope supply.
• FY 2026 revenue and other income expected to exceed US$1 billion.

What else do investors need to know?

Telix continues to expand its product pipeline, advancing multiple late-stage trials in prostate, brain, and kidney cancer. The company said U.S. dose volumes for its key commercial products rose slightly despite seasonal impacts, with September sales underpinning confidence in further annual growth.

Telix has also strengthened its manufacturing and supply capabilities. Through its Telix Manufacturing Solutions unit, the company expanded its U.S. micro-pharmacy network and secured more contracts for its isotope production technology. Its collaboration with Ekalia is expected to secure priority isotope access for new alpha therapy products.

On the corporate front, shareholders will vote in December on the ITM merger, a US$1.65 billion deal designed to create a vertically integrated leader in radiopharmaceuticals. The board welcomed David Gill as Chair and Marcin Firek as Company Secretary, further bolstering the company’s governance and leadership credentials.

What did Telix Pharmaceuticals management say?

Dr. Christian Behrenbruch, Managing Director and Group CEO, commented:

Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality. We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026. We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base. During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry’s broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities. This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale.

What’s next for Telix Pharmaceuticals?

Looking ahead, Telix expects FY 2026 revenue and other income to exceed US$1 billion, thanks to continued growth in its Precision Medicine business and increased commercial momentum from newly approved products. Revenue guidance factors in anticipated sales from Pixclara, a full-year contribution from RLS, and growth in key markets.

R&D spending guidance for the year was narrowed to US$240–260 million. The company’s development pipeline remains active, with trial results and regulatory milestones upcoming across its oncology portfolio, including a planned FDA resubmission for Zircaix and an expansion of Pixclara’s label. Integration planning for the ITM merger is also underway, aiming to boost Telix’s competitive position in targeted therapies.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have declined 7%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.

View Original Announcement

The post Telix Pharmaceuticals Q3 2026 earnings: revenue up, pipeline advances appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?
• UBS thinks Telix Pharmaceuticals shares will go how high?
• Here are the top 10 ASX 200 shares today
• Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.